Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site - 19/04/17
Doi : 10.1016/j.jaci.2016.09.014
Karin A. van Schie, MSc a, b, Simone Kruithof, BSc a, b, Pauline A. van Schouwenburg, PhD a, b, Anke Vennegoor, MD c, Joep Killestein, MD, PhD c, Gertjan Wolbink, MD, PhD a, b, d, Theo Rispens, PhD a, b 
a Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands
b Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
c Department of Neurology, Amsterdam Neuroscience, VUmc MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
d Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands
| Disclosure of potential conflict of interest: K. A. van Schie receives grant support from Pfizer. S. Kruithof receives grant support from Pfizer. A. Vennegoor receives payments for lectures from TEVA. J. Killestein serves as a consultant for Blogen Idec, Roche, Novartis, Merck-Serono, TEVA, and Genzyme and grant support from Blogen Idec, Novartis, TEVA, Bayer Schering Pharma, GlaxoSmithKline, and Merck-Serono. G. Wolbink receives grant support from Pfizer and payments for lectures from Pfizer, AbbVie, and UCB. T. Rispens receives grant support from Pfizer and Genmab; serves as a consultant for Genmab; and receives payments for lectures from Pfizer, Abbvie, and Reneneron. VUmc MS Center Amsterdam has received financial support for research activities from Bayer Schering Pharma, Biogen-Idec, GlaxoSmithKline, Merck-Serono, Novartis, Genzyme, Roche, and Teva. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 3
P. 1035 - mars 2017 Retour au numéro
Article précédent
- Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD
- Alina E. Dulau Florea, Raul C. Braylan, Kristian T. Schafernak, Kelli W. Williams, Janine Daub, Rakesh K. Goyal, Jennifer M. Puck, V. Koneti Rao, Stefania Pittaluga, Steven M. Holland, Gulbu Uzel, Katherine R. Calvo
- A pilot study to investigate the use of serum inhaled corticosteroid concentration as a potential marker of treatment adherence in severe asthma
- Kate E. George, Dorothy M. Ryan, Brian Keevil, Robert Niven, Stephen J. Fowler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?